Q2 EPS Estimate for PROCEPT BioRobotics Decreased by Analyst

PROCEPT BioRobotics Co. (NASDAQ:PRCT) – Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share estimates for PROCEPT BioRobotics in a research report issued to clients and investors on Monday, April 28th. Leerink Partnrs analyst M. Kratky now forecasts that the company will earn ($0.43) per share for the quarter, down from their prior forecast of ($0.39). The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.75) per share. Leerink Partnrs also issued estimates for PROCEPT BioRobotics’ Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.54) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.81) EPS, FY2028 earnings at ($0.23) EPS and FY2029 earnings at $0.23 EPS.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its quarterly earnings results on Thursday, April 24th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.04. The company had revenue of $69.16 million for the quarter, compared to analyst estimates of $65.39 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. PROCEPT BioRobotics’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.51) EPS.

A number of other research firms have also weighed in on PRCT. Bank of America reduced their price objective on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a “buy” rating on the stock in a research report on Friday, April 25th. Morgan Stanley decreased their price target on PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Finally, Truist Financial cut their price objective on PROCEPT BioRobotics from $90.00 to $70.00 and set a “buy” rating on the stock in a research report on Friday, April 11th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, PROCEPT BioRobotics currently has an average rating of “Moderate Buy” and a consensus target price of $90.00.

PROCEPT BioRobotics Trading Up 5.2 %

Shares of PRCT opened at $55.62 on Thursday. PROCEPT BioRobotics has a twelve month low of $47.04 and a twelve month high of $103.81. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21. The company’s fifty day simple moving average is $56.75 and its 200-day simple moving average is $73.36. The company has a market cap of $3.08 billion, a P/E ratio of -28.52 and a beta of 1.09.

Hedge Funds Weigh In On PROCEPT BioRobotics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Lord Abbett & CO. LLC boosted its holdings in shares of PROCEPT BioRobotics by 45.3% in the 3rd quarter. Lord Abbett & CO. LLC now owns 748,555 shares of the company’s stock valued at $59,974,000 after buying an additional 233,430 shares in the last quarter. Perpetual Ltd purchased a new position in PROCEPT BioRobotics in the fourth quarter worth $66,972,000. Oak Ridge Investments LLC increased its position in shares of PROCEPT BioRobotics by 24.0% during the fourth quarter. Oak Ridge Investments LLC now owns 30,059 shares of the company’s stock worth $2,420,000 after purchasing an additional 5,817 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of PROCEPT BioRobotics by 295.8% during the 4th quarter. SG Americas Securities LLC now owns 6,598 shares of the company’s stock valued at $531,000 after purchasing an additional 4,931 shares during the last quarter. Finally, Chicago Capital LLC boosted its position in shares of PROCEPT BioRobotics by 44.5% in the 4th quarter. Chicago Capital LLC now owns 379,582 shares of the company’s stock worth $30,564,000 after purchasing an additional 116,931 shares in the last quarter. Hedge funds and other institutional investors own 89.46% of the company’s stock.

Insider Buying and Selling

In other news, CFO Kevin Waters sold 733 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the transaction, the chief financial officer now directly owns 107,991 shares in the company, valued at approximately $6,161,966.46. This trade represents a 0.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Reza Zadno sold 5,475 shares of PROCEPT BioRobotics stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the transaction, the chief executive officer now owns 173,070 shares in the company, valued at $9,875,374.20. This represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,455 shares of company stock valued at $368,322 over the last quarter. 17.40% of the stock is owned by corporate insiders.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).